Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors

Antiviral Research

Volumn 132, Issue , 2016, Pages 186-195

  Villa, Juan Antonio ^a   Pike, Daniel P ^a   Patel, Kunjan B ^a   Lomonosova, Elena ^a   Lu, Gaofeng ^a,b   Abdulqader, Roz ^a   Tavis, John E ^a  

^a Saint Louis University   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

DNA virus; Endoribonuclease; Hepatitis B virus; Ribonuclease; RNA processing

Indexed keywords

ANTIVIRUS AGENT; DNA; EXORIBONUCLEASE; RECOMBINANT ENZYME; RECOMBINANT RIBONUCLEASE H; RIBONUCLEASE H; RNA; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN; VIRUS RNA;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; DNA RNA HYBRIDIZATION; DNA STRAND; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME PURIFICATION; ENZYME SPECIFICITY; HEPATITIS B VIRUS; HIGH THROUGHPUT SCREENING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; RNA CLEAVAGE; RNA DEGRADATION; SEQUENCE ANALYSIS; VIRUS STRAIN; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PROTEIN MULTIMERIZATION;

ANTIVIRAL AGENTS; DRUG DISCOVERY; GENE EXPRESSION; HEPATITIS B VIRUS; HUMANS; PROTEIN MULTIMERIZATION; RECOMBINANT PROTEINS; RIBONUCLEASE H; RNA CLEAVAGE; RNA, VIRAL; SUBSTRATE SPECIFICITY;

EID: 84976443899     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.06.005     Document Type: Article

References (59)

1. Abbondanzieri, E.A., Bokinsky, G., Rausch, J.W., Zhang, J.X., Le Grice, S.F., Zhuang, X., Dynamic binding orientations direct activity of HIV reverse transcriptase. Nature 453 (2008), 184–189.
2. Andersen, K.R., Leksa, N.C., Schwartz, T.U., Optimized E. coli expression strain LOBSTR eliminates common contaminants from His-tag purification. Proteins Struct. Funct. Bioinforma. 81 (2013), 1857–1861.
3. Arnold, E., Sarafianos, S.G., Molecular biology: an HIV secret uncovered. Nature 453 (2008), 169–170.
4. Block, T.M., Gish, R., Guo, H., Mehta, A., Cuconati, A., Thomas London, W., Guo, J.T., Chronic hepatitis B: what should be the goal for new therapies?. Antivir. Res. 98 (2013), 27–34.
5. Bolanos-Garcia, V.M., Davies, O.R., Structural analysis and classification of native proteins from E. coli commonly co-purified by immobilised metal affinity chromatography. Biochim. Biophys. Acta (BBA)-General Subj. 1760 (2006), 1304–1313.
6. Cai, C.W., Lomonosova, E., Moran, E.A., Cheng, X., Patel, K.B., Bailly, F., Cotelle, P., Meyers, M.J., Tavis, J.E., Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity. Antivir. Res. 108 (2014), 48–55.
7. Cao, F., Tavis, J.E., Detection and characterization of cytoplasmic hepatitis B virus reverse transcriptase. J. Gen. Virol. 85 (2004), 3353–3360.
8. Chen, Y., Marion, P.L., Amino acids essential for RNAse H activity of hepadnaviruses are also required for efficient elongation of minus-strand DNA. J. Virol. 70 (1996), 6151–6156.
9. Chen, Y., Robinson, W.S., Marion, P.L., Selected mutations of the duck hepatitis B virus P gene RNase H domain affect both RNA packaging and priming of minus-strand DNA synthesis. J. Virol. 68 (1994), 5232–5238.
10. Choi, J., Kim, E.E., Park, Y.I., Han, Y.S., Expression of the active human and duck hepatitis B virus polymerases in heterologous system of Pichia methanolica. Antivir. Res. 55 (2002), 279–290.
11. Coffin, C.S., Mulrooney-Cousins, P.M., Peters, M.G., van, M.G., Roberts, J.P., Michalak, T.I., Terrault, N.A., Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J. Viral Hepat. 18 (2011), 415–423.
12. Cox, N., Tillmann, H., Emerging pipeline drugs for hepatitis B infection. Expert. Opin. Emerg. Drugs 16 (2011), 713–729.
13. Crute, J., Lehman, I., Herpes simplex-1 DNA polymerase. Identification of an intrinsic 5′–3′exonuclease with ribonuclease H activity. J. Biol. Chem. 264 (1989), 19266–19270.
14. Dyda, F., Hickman, A.B., Jenkins, T.M., Engelman, A., Craigie, R., Davies, D.R., Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 266 (1994), 1981–1986.
15. Freed, E.O., Martin, M.A., HIVs and their replication. Knipe, D.M., Howley, P.M., Griffin, D.E., Lamb, R.A., Martin, M.A., Roizman, B., Straus, S.E., (eds.) Fields Virology, 2007, Lippincott Williams & Wilkins, Philadelphia, 2107–2185.
16. Ganem, D., Prince, A.M., Hepatitis B virus infection–natural history and clinical consequences. N. Engl. J Med. 350 (2004), 1118–1129.
17. Gerelsaikhan, T., Tavis, J.E., Bruss, V., Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis. J. Virol. 70 (1996), 4269–4274.
18. Gong, Y., Yao, E., Tavis, J.E., Evidence that the RNAseH activity of the duck hepatitis B virus is unable to act on exogenous substrates. BMC Microbiol., 1, 2001, 12.
19. Grandgenett, D.P., Green, M., Different mode of action of ribonuclease H in purified alpha and alpha beta ribonucleic acid-directed deoxyribonucleic acid polymerase from avian myeloblastosiss virus. J. Biol. Chem. 249 (1974), 5148–5152.
20. Hansen, J., Schultze, T., Mellert, W., Moelling, K., Identification and characterization of HIV-specific RNAseH by monoclonal antibody. EMBO J. 7 (1988), 239–243.
21. Hostomsky, Z., Hostomska, Z., Matthews, D.A., Ribonuclease H. Linn, S.M., Lloyd, R.S., Roberts, R.J., (eds.) Nulceases, 1993, Cold Spring Harbor Laboratory Press, Plainview, NY, 341–376.
22. Hu, J., Boyer, M., Hepatitis B virus reverse transcriptase and epsilon RNA sequences required for specific interaction in vitro. J. Virol. 80 (2006), 2141–2150.
23. Hu, J., Seeger, C., Hsp90 is required for the activity of a hepatitis b virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 93 (1996), 1060–1064.
24. Hu, Y., Cheng, X., Cao, F., Huang, A., Tavis, J.E., beta-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antivir. Res. 99 (2013), 221–229.
25. Kholod, N., Sivogrivov, D., Latypov, O., Mayorov, S., Kuznitsyn, R., Kajava, A.V., Shlyapnikov, M., Granovsky, I., Single substitution in bacteriophage T4 RNase H alters the ratio between its exo-and endonuclease activities. Mutat. Res./Fundam. Mol. Mech. Mutagen. 781 (2015), 49–57.
26. Klumpp, K., Hang, J.Q., Rajendran, S., Yang, Y., Derosier, A., Wong, K.I., Overton, H., Parkes, K.E., Cammack, N., Martin, J.A., Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res. 31 (2003), 6852–6859.
27. Ko, C., Shin, Y.C., Park, W.J., Kim, S., Kim, J., Ryu, W.S., Residues Arg703, Asp777, and Arg781 of the RNase H domain of hepatitis B virus polymerase are critical for viral DNA synthesis. J. Virol. 88 (2014), 154–163.
28. Kwon, H., Lok, A.S., Hepatitis B therapy. Nat. Rev. Gastroenterol. Hepatol. 8 (2011), 275–284.
29. Lapkouski, M., Tian, L., Miller, J.T., Le Grice, S.F., Yang, W., Complexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradation. Nat. Struct. Mol. Biol. 20 (2013), 230–236.
30. Lavanchy, D., Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 11 (2004), 97–107.
31. Lee, I.L., Hong, Y.B., Kim, Y., Rho, H.M., Jung, G., RNaseH activity of human hepatitis B virus polymerase expressed in Escherichia coli. Biochem. Biophys. Res. Commun. 233 (1997), 401–407.
32. Lima, W.F., Wu, H., Crooke, S.T., Human RNases H. Methods Enzymol. 341 (2001), 430–440.
33. Loeb, D.D., Hirsch, R.C., Ganem, D., Sequence-independent RNA cleavages generate the primers for plus strand DNA synthesis in hepatitis B viruses: implications for other reverse transcribing elements. EMBO J. 10 (1991), 3533–3540.
34. Lu, G., Lomonosova, E., Cheng, X., Moran, E.A., Meyers, M.J., Le Grice, S.F., Thomas, C.J., Jiang, J.K., Meck, C., Hirsch, D.R., D'Erasmo, M.P., Suyabatmaz, D.M., Murelli, R.P., Tavis, J.E., Hydroxylated tropolones inhibit hepatitis B virus replication by blocking the viral ribonuclease H activity. Antimicrob. Agents Chemother. 59 (2015), 1070–1079.
35. Marcellin, P., Heathcote, E.J., Buti, M., Gane, E., De Man, R.A., Krastev, Z., Germanidis, G., Lee, S.S., Flisiak, R., Kaita, K., Manns, M., Kotzev, I., Tchernev, K., Buggisch, P., Weilert, F., Kurdas, O.O., Shiffman, M.L., Trinh, H., Washington, M.K., Sorbel, J., Anderson, J., Snow-Lampart, A., Mondou, E., Quinn, J., Rousseau, F., Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359 (2008), 2442–2455.
36. Nowotny, M., Retroviral integrase superfamily: the structural perspective. EMBO Rep. 10 (2009), 144–151.
37. Nowotny, M., Gaidamakov, S.A., Crouch, R.J., Yang, W., Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell 121 (2005), 1005–1016.
38. Nowotny, M., Yang, W., Stepwise analyses of metal ions in RNase H catalysis from substrate destabilization to product release. EMBO J. 25 (2006), 1924–1933.
39. Potenza, N., Salvatore, V., Raimondo, D., Falanga, D., Nobile, V., Peterson, D.L., Russo, A., Optimized expression from a synthetic gene of an untagged RNase H domain of human hepatitis B virus polymerase which is enzymatically active. Protein Expr. Purif. 55 (2007), 93–99.
40. Radziwill, G., Zentgraf, H., Schaller, H., Bosch, V., The duck hepatitis B virus DNA polymerase is tightly associated with the viral core structure and unable to switch to an exogenous template. Virology 163 (1988), 123–132.
41. Schatz, O., Mous, J., Le Grice, S., HIV-1 RT-associated ribonuclease H displays both endonuclease and 3′–5′ exonuclease activity. EMBO J., 9, 1990, 1171.
42. Seeger, C., Zoulim, F., Mason, W.S., Hepadnaviruses. Knipe, D.M., Howley, P.M., (eds.) Fields Virology, 6 ed., 2013, Lippincott Williams & Wilkins, Philadelphia PA, 2185–2221.
43. Shepard, C.W., Simard, E.P., Finelli, L., Fiore, A.E., Bell, B.P., Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 28 (2006), 112–125.
44. Sorrell, M.F., Belongia, E.A., Costa, J., Gareen, I.F., Grem, J.L., Inadomi, J.M., Kern, E.R., McHugh, J.A., Petersen, G.M., Rein, M.F., Strader, D.B., Trotter, H.T., National institutes of health consensus development conference statement: management of hepatitis B. Ann. Intern. Med. 150 (2009), 104–110.
45. Summers, J., Mason, W.S., Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29 (1982), 403–415.
46. Tavis, J.E., Badtke, M.P., Hepadnaviral genomic replication. Cameron, C.E., Götte, M., Raney, K.D., (eds.) Viral Genome Replication, 2009, Springer Science+Business Media, LLC, New York, 129–143.
47. Tavis, J.E., Cheng, X., Hu, Y., Totten, M., Cao, F., Michailidis, E., Aurora, R., Meyers, M.J., Jacobsen, E.J., Parniak, M.A., Sarafianos, S.G., The hepatitis B virus ribonuclease h is sensitive to inhibitors of the human immunodeficiency virus ribonuclease h and integrase enzymes. PLoS Pathog., 9, 2013, e1003125.
48. Tavis, J.E., Gehring, A.J., Hu, Y., How further suppression of virus replication could improve current HBV treatment. Expert Rev. Anti-infect. Ther. 11 (2013), 755–757.
49. Tavis, J.E., Lomonosova, E., The hepatitis B virus ribonuclease H as a drug target. Antivir. Res. 118 (2015), 132–138.
50. van Bommel, F., De Man, R.A., Wedemeyer, H., Deterding, K., Petersen, J., Buggisch, P., Erhardt, A., Huppe, D., Stein, K., Trojan, J., Sarrazin, C., Bocher, W.O., Spengler, U., Wasmuth, H.E., Reinders, J.G., Moller, B., Rhode, P., Feucht, H.H., Wiedenmann, B., Berg, T., Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51 (2010), 73–80.
51. Wei, X., Peterson, D.L., Expression, purification, and characterization of an active RNase H domain of the hepatitis B viral polymerase. J. Biol. Chem. 271 (1996), 32617–32622.
52. Wendeler, M., Lee, H.F., Bermingham, A., Miller, J.T., Chertov, O., Bona, M.K., Baichoo, N.S., Ehteshami, M., Beutler, J., O'Keefe, B.R., Gotte, M., Kvaratskhelia, M., Le, G.S., Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity. ACS Chem. Biol. 3 (2008), 635–644.
53. Woehrl, B.M., Moelling, K., Interaction of HIV-1 ribonuclease H with polypurine tract containing RNA-DNA hybrids. Biochemistry 29 (1990), 10141–10147.
54. Woo, G., Tomlinson, G., Nishikawa, Y., Kowgier, M., Sherman, M., Wong, D.K., Pham, B., Ungar, W.J., Einarson, T.R., Heathcote, E.J., Krahn, M., Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 139 (2010), 1218–1229.
55. Wursthorn, K., Jung, M., Riva, A., Goodman, Z.D., Lopez, P., Bao, W., Manns, M.P., Wedemeyer, H., Naoumov, N.V., Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 52 (2010), 1611–1620.
56. Yang, W., Steitz, T.A., Recombining the structures of HIV integrase, RuvC and RNase H. Structure 3 (1995), 131–134.
57. Yao, E., Gong, Y., Chen, N., Tavis, J.E., The majority of duck hepatitis B virus reverse transcriptase in cells is nonencapsidated and is bound to a cytoplasmic structure. J. Virol. 74 (2000), 8648–8657.
58. Zhang, Z., Tavis, J.E., The duck hepatitis B virus reverse transcriptase functions as a full-length monomer. J. Biol. Chem. 281 (2006), 35794–35801.
59. Zoulim, F., Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?. Antivir. Chem. Chemother. 15 (2004), 299–305.